Literature DB >> 9236451

Crystalloid versus cold blood cardioplegia and cardiac troponin I release.

H Pichon1, S Chocron, K Alwan, G Toubin, D Kaili, P Falcoz, L Latini, F Clement, J F Viel, J P Etievent.   

Abstract

BACKGROUND: Cardiac troponin I (CTnI) has been shown to be a marker of myocardial injury. The aim of this study was to compare antegrade crystalloid cardioplegia with antegrade cold blood cardioplegia with warm reperfusion using CTnI release as the criteria for evaluating the adequacy of myocardial protection. METHODS AND
RESULTS: Seventy patients were randomly assigned to receive crystalloid or blood cardioplegia. CTnI concentrations were measured in serial venous blood samples drawn just before cardiopulmonary bypass and after aortic unclamping at 6, 9, 12, and 24 hours and daily thereafter for 5 days. ANOVA with repeated measures was performed to test the effect of the type of cardioplegia on CTnI release. The total amount of CTnI released was higher in the crystalloid cardioplegia group than in the blood cardioplegia group (11.2 +/- 8.9 versus 7.8 +/- 8.6 micrograms, P < .02). CTnI concentration was significantly higher in the crystalloid group than in the blood group in the samples drawn at hours 9 and 12. Three patients in each group had ECG evidence of perioperative myocardial infarction. Eight patients in the crystalloid group and five patients in the blood group had CTnI evidence of perioperative myocardial infarction. CTnI release was significantly lower in patients requiring no electrical defibrillation after aortic unclamping.
CONCLUSIONS: Cold blood cardioplegia followed by warm reperfusion is beneficial in an unselected group of patients with a preserved left ventricular function undergoing an elective first coronary artery bypass grafting. CTnI allowed the diagnosis of small perioperative necrotic myocardial areas. The need for electrical defibrillation after aortic unclamping was related to a higher release of CTnI. A further study is necessary to determine whether this technique was beneficial because of cold blood cardioplegia, warm reperfusion, or both.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236451

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris.

Authors:  P Fiorina; E Astorri; R Albertini; A Secchi; A Mello; M Lanfredini; A Craveri; G Olivetti; F Quaini
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

2.  AgNORs in cardiomyocytes from surgical patients with coronary heart disease.

Authors:  N N Mamaev; O V Kovalyeva; Kh K Amineva; I S Polykarpov; S N Proshin; L V Lebedev
Journal:  Mol Pathol       Date:  1998-08

3.  Myocardial apoptosis and injury of donor hearts kept in completely beating status with normothermic blood perfusion for transplants.

Authors:  Jun Kuang; Yanpeng Sun; Wei Wang; Han Ke; Hong Ye
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  Theoretical and Practical Aspects in the Use of Bretschneider Cardioplegia.

Authors:  Claudiu Ghiragosian; Marius Harpa; Alexandra Stoica; Flămînd Oltean Sânziana; Radu Bălău; Hussam Al Hussein; Ghiragosian-Rusu Simina Elena; Radu Mircea Neagoe; Horațiu Suciu
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-02

5.  Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance.

Authors:  Fernando Teiichi Costa Oikawa; Whady Hueb; Cesar Higa Nomura; Alexandre Ciappina Hueb; Alexandre Volney Villa; Leandro Menezes Alves da Costa; Rodrigo Morel Vieira de Melo; Paulo Cury Rezende; Carlos Alexandre Wainrober Segre; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Jose Antonio Franchini Ramires; Roberto Kalil Filho
Journal:  J Cardiothorac Surg       Date:  2017-12-29       Impact factor: 1.637

6.  [Kinetics of cTnI and threshold values for the diagnosis of myocardial infarction after cardiac surgery with cardiopulmonary bypass].

Authors:  Samy Kallel; Anwar Jarraya; Maged Ellouze; Imed Frikha; Abbdelhamid Karoui
Journal:  Pan Afr Med J       Date:  2012-12-29

7.  A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation.

Authors:  Johan Nilsson; Victoria Jernryd; Guangqi Qin; Audrius Paskevicius; Carsten Metzsch; Trygve Sjöberg; Stig Steen
Journal:  Nat Commun       Date:  2020-06-12       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.